“The present predicament has uncovered some structural weaknesses in the EU’s medicines supply chain plus a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She encouraged that supply chain problems be addressed in an EU pharmaceutical method predicted to be introduced by the end with the https://www.rilife.co/your-premier-supplier-of-active-pharmaceutical-ingredients-apis-in-india/